1. Home
  2. VLN vs AGEN Comparison

VLN vs AGEN Comparison

Compare VLN & AGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Valens Semiconductor Ltd.

VLN

Valens Semiconductor Ltd.

HOLD

Current Price

$1.34

Market Cap

157.6M

Sector

Technology

ML Signal

HOLD

Logo Agenus Inc.

AGEN

Agenus Inc.

HOLD

Current Price

$3.35

Market Cap

126.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
VLN
AGEN
Founded
2006
1994
Country
Israel
United States
Employees
N/A
N/A
Industry
Semiconductors
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
157.6M
126.2M
IPO Year
N/A
1999

Fundamental Metrics

Financial Performance
Metric
VLN
AGEN
Price
$1.34
$3.35
Analyst Decision
Strong Buy
Buy
Analyst Count
1
2
Target Price
$3.00
$14.50
AVG Volume (30 Days)
574.9K
403.0K
Earning Date
01-01-0001
06-22-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
0.37
Revenue
N/A
$42,877,086.00
Revenue This Year
N/A
N/A
Revenue Next Year
$16.99
$68.25
P/E Ratio
N/A
$8.89
Revenue Growth
N/A
89.95
52 Week Low
$1.30
$1.38
52 Week High
$3.34
$7.34

Technical Indicators

Market Signals
Indicator
VLN
AGEN
Relative Strength Index (RSI) 37.77 53.55
Support Level N/A $2.92
Resistance Level $1.63 $4.62
Average True Range (ATR) 0.07 0.21
MACD -0.00 0.01
Stochastic Oscillator 10.09 59.65

Price Performance

Historical Comparison
VLN
AGEN

About VLN Valens Semiconductor Ltd.

Valens Semiconductor Ltd is a provider of semiconductor products, pushing the boundaries of connectivity by enabling long-reach, high-speed video, and data transmission for the audio-video and automotive industries. It operates in two segments: Cross Industry Business, which includes solutions for the non-automotive verticals, including audio-video, industrial, machine vision and medical markets, that deliver superior, plug-and-play convergence and distribution of different interfaces, through a single long-distance category cable; and Automotive segment products enable safe and resilient high-speed in-vehicle connectivity for car architectures, realizing the vision of connected and autonomous cars. The company's geographical revenue is derived from Hungary.

About AGEN Agenus Inc.

Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).

Share on Social Networks: